AgomAb Therapeutics NV American Depositary Shares (AGMB) Stock
Key stats
- Market cap
- $344.24M
- Price / Earnings ratio
- -4.7x
- EPS (TTM)
- -$7.75
- Volume
- Loading
- 52-week high
- $17.82
- 52-week low
- $6.46
Source: third-party data provider, as of November 13, 2026
Compare with AGMB
Recent news

Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
AGMB

Agomab Therapeutics files for US IPO
Agomab Therapeutics files for US IPO
AGMB
Technical indicators
- RSI 14
- 33.73
- MACD 12/26/9
- -0.76
- EMA 9 of MACD
- -0.81
- MACD histogram
- 0.04
- SMA 50
- $9.89
- Price below SMA 50
- EMA 50
- $9.36
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
AGMB

Agomab Therapeutics files for US IPO
Agomab Therapeutics files for US IPO
AGMB
About AgomAb Therapeutics NV American Depositary Shares
The company is a clinical-stage biopharmaceutical organization focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial emphasis on chronic fibrotic conditions that have significant unmet medical needs. Its product candidates are designed to target established biological pathways and employ validated therapeutic modalities, with the goal of enhancing efficacy while minimizing systemic toxicities and addressing the limitations of prior treatment approaches.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Tim Knotnerus MSc, Ph.D. | CEO & Executive Director | 1983 |
| Mr. Pierre Kemula B.Sc. | Chief Financial Officer | 1974 |
| Mr. Paolo Michieli Ph.D. | Founder, Senior Advisor & Member of Scientific Advisory Board | — |
| Sofie Van Gijsel | Vice President of Investor Relations | — |
| Ms. Ellen Lefever | General Counsel | 1985 |
| Dr. Philippe Wiesel M.D. | Chief Medical Officer | 1967 |
| Dr. Paul Van Der Horst Ph.D. | Chief Business Officer | 1988 |
| Dr. Andrea Sáez Borderías Ph.D. | Chief Development Officer | 1982 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 33.73
- MACD 12/26/9
- -0.76
- EMA 9 of MACD
- -0.81
- MACD histogram
- 0.04
- SMA 50
- $9.89
- Price below SMA 50
- EMA 50
- $9.36
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $60.00
- Average
- $60.00
- High
- $60.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +9.4 | -35.3 | -7.9 | +0.5 | +13.5 | +8.4 | -2.6 | -18.0 | -13.4 | +4.0 |



